China NT Pharma Group Co., Ltd. stock analysis
Want to see HK:1011 full AI Analyst Report?
China NT Pharma Group Co., Ltd. (1011) Stock Price & Analysis
1011 Stock Chart & Stats
- Day’s Range
- HKD 0.19 - HKD 0.20
- 52-Week Range
- HKD 0.16 - HKD 1.00
- Previous Close
- HKD 0.21
- Volume
- N/A
- Average Volume (3M)
- 394.99K
- Market Cap
- HKD 346.74M
- Enterprise Value
- HKD 787.72M
- Total Cash (Recent Filing)
- HKD 11.91M
- Total Debt (Recent Filing)
- HKD 334.93M
- Price to Earnings (P/E)
- ―
- Beta
- 1.10
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Jul 10, 2018
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Specialty And Branded Pharmaceutical Platform
A presence across drug development, manufacturing, commercialization, and distribution gives the company multiple ways to capture value from its products. Its specialty and branded focus can support differentiated market positioning and recurring demand if product adoption is sustained.
Recent Revenue Rebound
The return to revenue growth after the earlier decline indicates that the company has regained some commercial momentum. If maintained, broader sales can improve fixed-cost absorption, support investment in products, and provide a foundation for future operating recovery.
Improving Gross Margin
The substantial gross-margin improvement suggests that the product mix or commercial economics became more favorable. Continued margin improvement could strengthen the earnings model, increase the contribution from incremental sales, and help narrow the gap between revenue growth and profitability.
Bears Say
Persistent Severe Unprofitability
Recurring losses at this magnitude show that revenue growth has not yet translated into a sustainable operating model. The wide gap between sales and both operating and net earnings limits internal funding capacity and makes a durable turnaround dependent on substantial cost improvement.
Stressed Capital Structure
Negative equity and high debt materially reduce financial flexibility and leave the company more exposed to refinancing and solvency pressure. This capital structure can constrain investment in products and commercialization while increasing the consequences of continued operating losses.
Recurring Cash Consumption
The renewed cash burn indicates that reported commercial recovery has not yet produced dependable cash generation. Persistent negative operating and free cash flow can increase reliance on external financing, limit strategic flexibility, and amplify execution risk while losses continue.
China NT Pharma Group Co., Ltd. News
1011 FAQ
What was China NT Pharma Group Co., Ltd.’s price range in the past 12 months?
What is China NT Pharma Group Co., Ltd.’s market cap?
When is China NT Pharma Group Co., Ltd.’s upcoming earnings report date?
How were China NT Pharma Group Co., Ltd.’s earnings last quarter?
Is China NT Pharma Group Co., Ltd. overvalued?
Does China NT Pharma Group Co., Ltd. pay dividends?
What is China NT Pharma Group Co., Ltd.’s EPS estimate?
How many shares outstanding does China NT Pharma Group Co., Ltd. have?
What happened to China NT Pharma Group Co., Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of China NT Pharma Group Co., Ltd.?
What is the TipRanks Smart Score and how is it calculated?
China NT Pharma Group Co., Ltd. Stock Smart Score
Company Description
China NT Pharma Group Co., Ltd.
China NT Pharma Group Company Limited, operating alongside its various subsidiaries, is dedicated to the full spectrum of pharmaceutical activities. This encompasses the research, development, manufacturing, commercialization, and distribution of medicinal products, serving both the People's Republic of China and international territories. The firm develops and markets prescription medications addressing a diverse array of medical conditions, including oncological and hematological diseases, gastrointestinal disorders, central nervous system afflictions, and respiratory illnesses, among other therapeutic fields. In addition to these specialized drugs, it also produces and distributes its proprietary "NT" branded products and generic formulations. Furthermore, the group extends its offerings to include marketing and promotional assistance for suppliers, alongside providing logistics and consulting solutions. Established in 1995, the company maintains its corporate headquarters in Suzhou, People's Republic of China.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Bozhi Zhang
- Employees
- 32
- Website
- www.ntpharma.com
- Address
- HK
China NT Pharma Group Co., Ltd. (1011) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |







